In the wake of mass restructuring efforts across the Department of Health and Human Services, the FDA has missed yet another ...

During his first term, attempts by President Donald Trump to slash drug price | After failing in his first term to install a ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Amneal Pharmaceuticals inked a collaboration deal with syringe maker Apiject that will see the New Jersey-based biopharma ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump ...

Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. | Johnson & Johnson ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

The executive order adds on to Trump’s planned tariffs on pharmaceuticals in his overall strategy to onshore production of ...